![David Hunt](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
David Hunt
Fondateur chez Valocor Therapeutics, Inc.
Postes actifs de David Hunt
Sociétés | Poste | Début | Fin |
---|---|---|---|
Valocor Therapeutics, Inc.
![]() Valocor Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Valocor Therapeutics is a clinical-stage, privately-held company dedicated to developing innovative treatments for major unmet needs in dermatology. The company's portfolio of dermatology therapeutics includes Lemuteporfin, a potent and selective topical photodynamic therapy for moderate to severe acne and a portfolio of novel, topical small molecule therapeutics targeting acne, sebaceous gland hyperactivity, skin pigmentation disorders and inflammatory skin diseases. Valocor Therapeutics is headquartered in Vancouver, British Columbia. Although many common yet serious skin conditions have unsatisfactory treatment options, dermatology has in recent years attracted limited research resources and investment. As a result, a sparse pipeline and a lack of true scientific innovation have been the dominant themes of this field for the last twenty years. During this same period, technological advances have produced new research techniques that have greatly expanded its ability to study disease processes and establish new effective therapeutic strategies. Much of this innovative research has been applied to the fields such as oncology, autoimmunity, and ocular diseases. Valocor is applying current biotechnology techniques to develop breakthrough therapies for major dermatological diseases, where prevalent conditions, minimal competition and important medical needs exist. | Directeur Technique/Scientifique/R&D | 26/05/2010 | - |
Fondateur | - | - |
Historique de carrière de David Hunt
Anciens postes connus de David Hunt
Sociétés | Poste | Début | Fin |
---|---|---|---|
QLT, Inc.
![]() QLT, Inc. Miscellaneous Commercial ServicesCommercial Services QLT, Inc. is a biotechnology company, which engages in the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide. It also focuses on developing synthetic retinoid program for the treatment of certain inherited retinal diseases. The company was founded by Julia G. Levy and John C. Brown on February 3, 1981 and is headquartered in Vancouver, Canada. | Corporate Officer/Principal | - | - |
Formation de David Hunt
University of British Columbia | Doctorate Degree |
Statistiques
Internationale
Canada | 4 |
Opérationnelle
Chief Tech/Sci/R&D Officer | 1 |
Founder | 1 |
Corporate Officer/Principal | 1 |
Sectorielle
Commercial Services | 2 |
Consumer Services | 2 |
Health Technology | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Entreprise privées | 2 |
---|---|
QLT, Inc.
![]() QLT, Inc. Miscellaneous Commercial ServicesCommercial Services QLT, Inc. is a biotechnology company, which engages in the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide. It also focuses on developing synthetic retinoid program for the treatment of certain inherited retinal diseases. The company was founded by Julia G. Levy and John C. Brown on February 3, 1981 and is headquartered in Vancouver, Canada. | Commercial Services |
Valocor Therapeutics, Inc.
![]() Valocor Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Valocor Therapeutics is a clinical-stage, privately-held company dedicated to developing innovative treatments for major unmet needs in dermatology. The company's portfolio of dermatology therapeutics includes Lemuteporfin, a potent and selective topical photodynamic therapy for moderate to severe acne and a portfolio of novel, topical small molecule therapeutics targeting acne, sebaceous gland hyperactivity, skin pigmentation disorders and inflammatory skin diseases. Valocor Therapeutics is headquartered in Vancouver, British Columbia. Although many common yet serious skin conditions have unsatisfactory treatment options, dermatology has in recent years attracted limited research resources and investment. As a result, a sparse pipeline and a lack of true scientific innovation have been the dominant themes of this field for the last twenty years. During this same period, technological advances have produced new research techniques that have greatly expanded its ability to study disease processes and establish new effective therapeutic strategies. Much of this innovative research has been applied to the fields such as oncology, autoimmunity, and ocular diseases. Valocor is applying current biotechnology techniques to develop breakthrough therapies for major dermatological diseases, where prevalent conditions, minimal competition and important medical needs exist. | Health Technology |
- Bourse
- Insiders
- David Hunt
- Expérience